SCHEMBL330545

SCHEMBL330545

O=C(O)c1cc(Br)cc(Br)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 1.00
AKR1C2 P52895 3/20 1.00
AKR1C1 Q04828 3/20 1.00
AKR1C4 P17516 2/20 1.00
PTPN1 P18031 4/20 0.62
CYP3A4 P08684 1/20 0.56
TSHR P16473 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
PTPN2 P17706 1/20 0.56
PTPN6 P29350 1/20 0.56
HSPD1 P10809 2/20 0.56
HSPE1 P61604 2/20 0.56
HSD17B10 Q99714 1/20 0.55
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
EGFR P00533 1/20 0.53
LMNA P02545 1/20 0.53
ERBB2 P04626 1/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29387062 1.00 AKR1C3 (1.00) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
SCHEMBL9398455 0.98 AKR1C3 (0.96) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
SCHEMBL9398446 0.98 AKR1C3 (0.96) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
SCHEMBL9398447 0.98 AKR1C3 (0.96) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
SCHEMBL9019697 0.98 AKR1C3 (0.96) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
Hydrochloric Acid SCHEMBL11781789 0.98 AKR1C3 (0.96) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
Water SCHEMBL9399153 0.96 AKR1C3 (0.92) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
Water SCHEMBL9399165 0.96 AKR1C3 (0.92) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
Fumaric Acid SCHEMBL27584103 0.90 AKR1C3 (0.81) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1
Fumaric Acid SCHEMBL28077711 0.90 AKR1C3 (0.81) AKR1C3AKR1C2AKR1C1AKR1C4PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND KAO CORPORATION (JP) 2025-07-03 US claimed
EP-4501896-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND Kao Corporation (JP) 2025-02-05 EP claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-114082936-B Gold nanorod synthesis method with good monodispersity 杭州电子科技大学 2024-05-24 CN claimed
CN-114113370-B Analysis method of aromatic halogenated disinfection byproducts in water 东南大学 2024-03-26 CN claimed
CN-115722210-B Recursive nanofiber-based detection material and preparation method and application thereof 广西大学 2024-02-20 CN claimed
CN-117402494-A Complex high-strength polyarylene sulfide based composite material and preparation and application thereof 新凝合科技(成都)有限公司 2024-01-16 CN claimed
WO-2023189722-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND 花王株式会社 2023-10-05 WO claimed
CN-113929991-B Scorch-resistant CR unvulcanized rubber stored at room temperature for long time, preparation method thereof and preparation method of scorch inhibitor 株洲时代瑞唯减振装备有限公司 2023-05-30 CN claimed
CN-115722210-A Recursive nanofiber-based detection material and preparation method and application thereof 广西大学 2023-03-03 CN claimed
EP-0031561-B1 A RECTALLY ADMINISTERED SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT MERCK & CO. INC. (US) 1985-04-10 EP claimed
US-4470980-A Method of increasing oral absorption of β-lactam antibiotics INTERX RESEARCH CORP. (US) 1984-09-11 US claimed
US-4464363-A HYDROXY ARYL- OR HYDROXY ARALKYL ACIDS OR SALTS MERCK & CO., INC. (US) 1984-08-07 US claimed
US-4406896-A ANTIBIOTICS, ACIDS, HYDROXY MERCK & CO., INC. (US) 1983-09-27 US claimed
EP-0036534-A1 An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-30 EP claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
EP-0035770-A2 An orally administered drug form comprising a glycosidic antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-16 EP claimed
US-4288543-A SAMPLING IN LIQUID PHASE WITH ANTIGROWTH AGENTS-BIOLOGICAL PFIZER INC. (US) 1981-09-08 US claimed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP claimed
US-3995034-A FUNGICIDES AND BACTERICIDES GAF CORPORATION (US) 1976-11-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND HSD17B7, HSD17B12, BCKDK AKR1C3 68/4885AKR1C2 38/4885AKR1C1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.